Skip to main content
Terug
Watch Compare

Universe Pharmaceuticals INC

Datakwaliteit: 100%
UPC
Nasdaq Manufacturing Chemicals
€ 2,95
▼ € 0,20 (-6,35%)
Marktkapitalisatie: 1,66 M
Prijs
€ 2,95
Marktkapitalisatie
1,66 M
Dagbereik
€ 2,86 — € 3,16
52-Weeksbereik
€ 2,00 — € 11,00
Volume
3.200
Openen € 3,16
50D / 200D Gem.
€ 3,08
4,31% below
50D / 200D Gem.
€ 3,86
23,58% below

Quick Summary

Belangrijkste Punten

Revenue grew 339,23% annually over 5 years — strong growth
Debt/Equity of 0,05 — conservative balance sheet
Negative free cash flow of -5,32 B
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 77124,95%
Capital efficient — spends only 1,49% of revenue on capex

Groei

Revenue Growth (5Y)
339,23%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)77464,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-9941,84%
Onder sectorgemiddelde (-53,47%)
ROIC-5659,17%
Net Margin-20,56%
Op. Margin-16,33%

Veiligheid

Debt / Equity
0,05
Onder sectorgemiddelde (0,31)
Current Ratio1,63
Interest Coverage-10,08

Waardering

PE (TTM)
0,00
Boven sectorgemiddelde (-1,47)
P/B Ratio0,06
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 0,0 -1,5
P/B 0,1 1,6
ROE % -9941,8 -53,5
Net Margin % -20,6 -41,5
Rev Growth 5Y % 339,2 1,8
D/E 0,1 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 77464,18% Revenue Growth (3Y) 2009,21%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 339,23% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 17,86 B Net Income (TTM) -3,67 B
ROE -9941,84% ROA -6130,34%
Gross Margin 35,28% Operating Margin -16,33%
Net Margin -20,56% Free Cash Flow (TTM) -5,32 B
ROIC -5659,17% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,05 Current Ratio 1,63
Interest Coverage -10,08 Asset Turnover 298,14
Working Capital 12,92 M Tangible Book Value 26,60 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0,00 Forward P/E N/A
P/B Ratio 0,06 P/S Ratio 0,00
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -320070,98%
Market Cap 1,66 M Enterprise Value 3,05 M
Per Share
EPS (Diluted TTM) -8,06 Revenue / Share 31701,68
FCF / Share -9442,11 OCF / Share -8968,56
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,49% FCF Conversion 144,85%
SBC-Adj. FCF N/A Growth Momentum 77124,95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023 FY2021
Revenue 17,86 B 23,02 M 40,14 M 32,31 M 47,98 M
Net Income -3,67 B -8,73 M -8,74 M -6,16 M 11,32 M
EPS (Diluted) -8,06 -626,96 -0,40 -1,70 —
Gross Profit 6,30 B 6,07 M 21,89 M 10,32 M 25,33 M
Operating Income -2,92 B -8,02 M — -3,53 M 13,59 M
EBITDA — — — — —
R&D Expenses 671,76 M 3,03 M 7,64 M 4,86 M 5,47 M
SG&A Expenses — — — — —
D&A 517,43 M 485.734,0 533.949,0 508.785,0 446.878,0
Interest Expense 289,39 M 278.172,0 162.400,0 156.788,0 101.604,0
Income Tax 606,70 M 606.704,0 752.419,0 2,31 M 2,36 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023 FY2021
Total Assets 69,30 B 67,95 M 59,54 M 53,29 M 70,14 M
Total Liabilities 13,17 B 22,45 M — — —
Shareholders' Equity 56,13 B 45,50 M 46,44 M 39,53 M 58,93 M
Total Debt 7,15 B 5,86 M 3,94 M 1,37 M 4,33 M
Cash & Equivalents — — — — 8,08 M
Current Assets 53,60 B 51,64 M 41,51 M 36,81 M 50,48 M
Current Liabilities 13,17 B 20,31 M 13,10 M 13,75 M 11,21 M